Thin
T2D & Obesity
Direct supply from state-of-the-art solid-phase peptide synthesis (SPPS) facilities. Guaranteed analytical purity ≥ 98.5%, mass spectrometry confirmation, and complete batch documentation tailored for SFDA dossier filings.
Evaluating epidemiological surges, NUPCO procurement models, and the imperative for resilient peptide API manufacturing partnerships.
The Kingdom of Saudi Arabia (KSA) faces one of the world's most acute metabolic disease burdens. According to clinical data published by the International Diabetes Federation (IDF) and the Saudi Ministry of Health (MoH), over 18.7% of the adult Saudi population is diagnosed with Type 2 Diabetes Mellitus (T2D), while age-adjusted adult obesity exceeds 35%. This health crisis has elevated Glucagon-Like Peptide-1 (GLP-1) receptor agonists—such as Semaglutide, Tirzepatide, and Dulaglutide—from elective therapeutic options to national health security assets.
Under the transformative framework of Saudi Vision 2030, the Health Sector Transformation Program (HSTP) is actively pivoting from downstream disease management to aggressive early clinical intervention and metabolic normalization. Consequently, the centralized medical procurement body—National Unified Procurement Company (NUPCO)—has experienced exponential surges in tender volumes for incretin mimetics. However, global supply crunches and brand-name shortages have spurred Saudi pharma companies, local CDMOs, and compounding institutions to seek robust, high-volume peptide API manufacturers capable of providing commercial continuity, compliant documentation, and multi-ton scalability.
The Saudi Ministry of Industry and Mineral Resources, in coordination with the Local Content and Government Procurement Authority (LCGPA), offers substantial procurement preferences for pharmaceuticals formulated domestically. Emerging biotech clusters within the King Salman Energy Park (SPARK), Sudair Industrial City, and King Abdullah Economic City (KAEC) are actively seeking qualified active pharmaceutical ingredient (API) suppliers to support local bio-manufacturing, fill-finish operations, and clinical-grade custom synthesis.
The Saudi Food and Drug Authority (SFDA) enforces strict regulatory standards aligned with ICH guidelines, demanding complete eCTD Module 3 technical documentation, validation of related substances, and rigorous endotoxin control. Furthermore, given Saudi Arabia's arid, high-temperature climate (often exceeding 45°C in summer), pharmaceutical APIs and lyophilized peptides require absolute cold-chain compliance (2°C to 8°C or -20°C) via specialized thermo-monitored logistics corridors connecting Hangzhou to Riyadh King Khalid International Airport.
Bridging global capacity shortfalls through cutting-edge chemical synthesis, backward-integrated amino acid supply, and multi-ton production efficiency.
While early innovator GLP-1s utilized recombinant DNA yeast fermentation, modern synthetic peptide chemistry—leveraging fully automated Solid-Phase Peptide Synthesis (SPPS) and hybrid fragment condensation—offers superior batch turnaround, zero host-cell protein (HCP) contamination, and streamlined scalability for multi-ton industrial batches.
Thinheal operates an integrated supply network originating from raw amino acid precursors, specialized protecting groups (Fmoc/tBu), and high-efficiency coupling reagents (HATU/HBTU) directly into production reactors in Hangzhou. This eliminates reliance on third-party raw material intermediaries, shielding Saudi partners from global supply-chain choke points.
By optimizing solvent recovery, implementing continuous preparative HPLC purification columns, and leveraging multi-ton reactor volume capacity, Chinese production centers deliver cost advantages of 40% to 65% compared to European or North American peptide custom synthesis labs, granting Saudi distributors unmatched commercial flexibility.
| Evaluation Parameter | Thinheal Advanced Chemical SPPS | Traditional Recombinant Fermentation | Generic CDMO Competitors |
|---|---|---|---|
| Synthesis Cycle Time | 12 – 16 days (High throughput) | 45 – 60 days (Fermentation & Cleavage) | 25 – 35 days |
| Batch Capacity | Multi-kilogram to Multi-ton campaigns | Fixed bioreactor constraints | Grams to 5 kg maximum |
| Impurity Profile | No host-cell proteins (HCP) or DNA contaminants | Requires intense viral/HCP clearance testing | Variable D-amino acid racemization rates |
| Purity Levels (RP-HPLC) | ≥ 99.0% (Custom ≥ 99.5% available) | Typically 96.5% – 98.0% | 97.0% – 98.5% |
| Regulatory Readiness | Complete SFDA/ICH DMF, stability packages | Complex biosimilar comparability files | Basic CoA only, limited regulatory support |
From single GLP-1 receptor targeting to unimolecular poly-agonists and oral bioavailable formulation actives.
The metabolic therapeutic landscape has evolved through distinct technological generations. First-generation agonists like Exenatide and Liraglutide established the biological proof-of-concept for glycemic control. Second-generation Semaglutide extended plasma half-life to approximately 165 hours via albumin-binding diacid acylation (Lys26 modification with AEEA-AEEA-γ-Glu-17-carboxyheptadecanoyl), enabling convenient once-weekly dosing.
Today, the clinical frontier in Saudi Arabia and worldwide belongs to multi-target co-agonists:
In adherence to global ESG standards and Saudi Green Initiative mandates, modern synthesis suites replace hazardous solvents like DMF and NMP with bio-derived, sustainable alternative solvents (such as 2-MeTHF and Cyrene). High-efficiency microwave-assisted coupling and automated PAT (Process Analytical Technology) ensure minimal batch wastage and high atom economy.
Peptide synthesis demands rigorous tracking of deletion peptides, truncated chains, and β-aspartyl rearrangements. Employing ultra-high performance liquid chromatography coupled with Orbitrap high-resolution mass spectrometry (UHPLC-HRMS), our batch analytics guarantee that critical related substances remain well below ICH Q3A/B reporting thresholds.
Transparent reference benchmarks for procurement directors, university research centers, and pharmaceutical manufacturers across Riyadh, Jeddah, and the GCC.
| Target Compound / CAS | Therapeutic Class | Standard Purity | Pilot Batch (10g – 100g) | Commercial Tier (1kg – 10kg) | Industrial Tier (>10kg / Annual) | Availability |
|---|---|---|---|---|---|---|
| Semaglutide CAS: 910463-68-2 |
GLP-1 Receptor Agonist | ≥ 99.0% | $140 – $180 / g | $45,000 – $65,000 / kg | Inquire for Contract Pricing | In Stock / Scale-Ready |
| Tirzepatide CAS: 2023788-19-2 |
Dual GIP/GLP-1 Agonist | ≥ 99.0% | $160 – $210 / g | $55,000 – $78,000 / kg | Inquire for Contract Pricing | Commercial Production |
| Retatrutide CAS: 2381089-83-2 |
Triple GLP-1/GIP/GCGR | ≥ 98.5% | $220 – $290 / g | $75,000 – $105,000 / kg | Custom Campaign CDMO | Fast-Track Batch |
| Dulaglutide CAS: 923950-08-7 |
Long-Acting GLP-1 RA | ≥ 98.5% | $190 – $250 / g | $65,000 – $88,000 / kg | Inquire for Scale Quotes | In Stock |
| Selank Peptide CAS: 129954-34-3 |
Regulatory Neuro-Peptide | ≥ 98.5% | $45 – $75 / g | $18,000 – $26,000 / kg | Volume Discount Available | Immediate Dispatch |
| Semax Peptide CAS: 80714-61-0 |
CNS & Metabolic Enhancer | ≥ 98.5% | $50 – $80 / g | $19,000 – $28,000 / kg | Volume Discount Available | Immediate Dispatch |
| MOTS-c 16 Amino Acids Active |
Mitochondrial Peptide | ≥ 98.0% | $60 – $95 / g | $22,000 – $32,000 / kg | Custom Scale Campaigns | In Stock |
*Note: The prices indicated above are FOB Shanghai/Hangzhou reference estimates. Commercial orders include customized TFA or Acetate salt conversion, analytical batch release CoA, residual solvent audits, and cold-chain thermal packaging compliant with SFDA port clearance standards. Contact our Middle East Desk for exact quotes.
Ensuring zero friction in customs clearance, regulatory qualification, and local market commercialization across the Gulf Cooperation Council.
We provide full Drug Master File (DMF) technical packages aligned with ICH Common Technical Document (CTD) Module 3. This includes detailed synthetic route description, critical quality attributes (CQAs), process validation, impurity tracing, and forced degradation studies.
Shipped via validated cryogenic dry-ice and phase-change material (PCM) packaging with VIP (Vacuum Insulated Panel) shippers. Equipped with real-time GPS and temperature dataloggers, guaranteeing adherence to 2°C – 8°C or -20°C standards from our Hangzhou facility to King Khalid or King Abdulaziz International Airports.
Our multilingual sales, QA, and regulatory team aligns directly with Gulf Standard Time (GST/AST). We support Saudi buyers with SASO certifications, legalization of commercial invoices, Certificates of Origin, and technical conference calls with our Chief Scientific Officers.
Addressing core technical, regulatory, and supply chain questions from institutional procurement teams and clinical researchers.
Explore our full active portfolio covering CNS enhancement, metabolic regulation, endocrine signaling, and clinical-grade custom incretins.
Whether you are preparing a NUPCO tender bid, engineering a local fill-finish facility, or conducting advanced metabolic clinical trials in the GCC, our dedicated Middle East Desk is prepared with comprehensive technical dossiers, batch samples, and contract pricing.